ROCHE HOLDINGS AG (RHHBY)

33.83
0.07 0.21
OTC
Prev Close 33.76
Open 33.87
Day Low/High 33.74 / 33.93
52 Wk Low/High 26.30 / 34.98
Volume 399.60K
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)
FDA Approves Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Adults With Extensive-Stage Small Cell Lung Cancer

FDA Approves Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Adults With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Genentech's Tecentriq In Combination With Abraxane Accelerated Approval For People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

FDA Grants Genentech's Tecentriq In Combination With Abraxane Accelerated Approval For People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

Genentech Submits Supplemental New Drug Application To FDA For Venclexta Plus Gazyva For Previously Untreated Chronic Lymphocytic Leukemia With Co-Existing Medical Conditions

Genentech Submits Supplemental New Drug Application To FDA For Venclexta Plus Gazyva For Previously Untreated Chronic Lymphocytic Leukemia With Co-Existing Medical Conditions

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the submission of a supplemental New Drug Application to the U.

FDA Accepts Genentech's Supplemental New Drug Application For XOFLUZA (baloxavir Marboxil) For The Treatment Of Influenza In People At High Risk Of Complications

FDA Accepts Genentech's Supplemental New Drug Application For XOFLUZA (baloxavir Marboxil) For The Treatment Of Influenza In People At High Risk Of Complications

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Herceptin Hylecta For Subcutaneous Injection In Certain HER2-Positive Breast Cancers

FDA Approves Herceptin Hylecta For Subcutaneous Injection In Certain HER2-Positive Breast Cancers

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto

3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto

ETFs could see big inflows again and Sparks stock soars; these are among the important market items today.

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

Dow Closes Modestly Higher After Trump Extends China Tariff Deadline

The Dow Jones Industrial Average rose modestly Monday after Donald Trump said he will delay increasing tariffs on China-made goods.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts

Spark Therapeutics shares more than double Monday after the gene therapy specialist agreed to a $4.3 billion takeover by Switzerland-based Roche Holding, the world's biggest maker of cancer treatments.

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died

Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.

Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know

Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know

U.S. stock futures rise after Donald Trump says he will delay increasing tariffs on China-made goods; Swiss drug giant Roche to buy Spark Therapeutics for about $4.8 billion; Warren Buffett wants to make an 'elephant-sized acquisition'; Kraft Heinz reportedly reviewing options for Maxwell House.

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress

StocksGlobal stocks traded higher Monday after President Donald Trump said he would delay the increase of tariffs on China-made goods, set to kick-in on March 1, following "substantial progress" over two weeks of trade talks between Washington and Beijing.

Roche to Buy Spark for $4.8 Billion

Roche to Buy Spark for $4.8 Billion

The price is nearly $3 billion over Spark's market cap of $1.95 billion as of Friday's close. Deal is slated to close in the second quarter of 2019.

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Roche Aims to Buy Spark for $5 Billion: Wall Street Journal

Predicted price would be nearly $3 billion over Spark's market cap as of Friday's close, but Roche spokesman claims report is 'market rumor.'

FDA Grants Priority Review To Genentech's Polatuzumab Vedotin In Previously Treated Aggressive Lymphoma

FDA Grants Priority Review To Genentech's Polatuzumab Vedotin In Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Priority Review To Genentech's Personalized Medicine Entrectinib

FDA Grants Priority Review To Genentech's Personalized Medicine Entrectinib

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Submits Supplemental Biologics License Application To FDA For Kadcyla For Adjuvant Treatment Of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech Submits Supplemental Biologics License Application To FDA For Kadcyla For Adjuvant Treatment Of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced completing the submission of a supplemental Biologics License Application to the U.

Genentech To Discontinue Phase III CREAD 1 And 2 Clinical Studies Of Crenezumab In Early Alzheimer's Disease (AD) - Other Company Programs In AD Continue

Genentech To Discontinue Phase III CREAD 1 And 2 Clinical Studies Of Crenezumab In Early Alzheimer's Disease (AD) - Other Company Programs In AD Continue

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early...

Roche Launches UPath Enterprise Software With Improved Speed, Performance And Usability For Digital Pathology

Roche Launches UPath Enterprise Software With Improved Speed, Performance And Usability For Digital Pathology

- Innovative design integrates powerful imaging and analysis tools for more efficient workflow

Roche To Develop Companion Diagnostic Test To Help Identify Patients Eligible For Anti-PD-1 Therapy Based On Biomarker Expression, Not Location, Of Solid Tumors

Roche To Develop Companion Diagnostic Test To Help Identify Patients Eligible For Anti-PD-1 Therapy Based On Biomarker Expression, Not Location, Of Solid Tumors

- Roche collaborates with Merck to develop companion diagnostic for use with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in advanced solid tumors with mismatch repair deficiency (dMMR)

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks finished the day higher on Monday as gains by tech stocks offset concerns over the fate of U.S.-China trade talks, and after the U.K. delayed a parliamentary vote on Brexit.

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Gilead Sciences Names Roche's O'Day as CEO and Chairman

Daniel O'Day will take over the helm of the biopharmaceutical giant on March 1, 2019.

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

U.S. stock futures turn mixed as investors continue to express concerns over the fate of U.S.-China trade talks; Tesla's Elon Musk says, 'I do not respect the SEC'; Carlos Ghosn and Nissan are indicted in Japan for underreporting the former chairman's pay.

FDA Approves Genentech's Tecentriq In Combination With Avastin And Chemotherapy For The Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

FDA Approves Genentech's Tecentriq In Combination With Avastin And Chemotherapy For The Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Kadcyla Cut The Risk Of Disease Recurring By Half Compared To Herceptin In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech's Kadcyla Cut The Risk Of Disease Recurring By Half Compared To Herceptin In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease...

FDA Grants Priority Review To Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Extensive-Stage Small Cell Lung Cancer

FDA Grants Priority Review To Genentech's Tecentriq In Combination With Chemotherapy For The Initial Treatment Of Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech's Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control In The Largest Pivotal Study To Date Of Children With Hemophilia A With Factor VIII Inhibitors

Genentech's Hemlibra (emicizumab-kxwh) Provided Sustained Bleed Control In The Largest Pivotal Study To Date Of Children With Hemophilia A With Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from the primary analysis of the Phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab-kxwh) prophylaxis in children younger than 12 years of age with hemophilia...

New Venclexta® Data Demonstrate Deep Responses In Two Of The Most Common Types Of Leukemia

New Venclexta® Data Demonstrate Deep Responses In Two Of The Most Common Types Of Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data from the Venclexta ® (venetoclax) clinical development program, including longer-term results from the Phase III MURANO study in people with previously treated...

Roche Launches First IVD Pan-TRK Immunohistochemistry Assay

Roche Launches First IVD Pan-TRK Immunohistochemistry Assay

- The VENTANA pan-TRK (EPR17341) Assay[1] is the first assay of its type to detect tropomyosin receptor kinase (TRK) with anticipated use across multiple solid tumor types